Abstract
Monoamine oxidase (MAO) catalyzes the oxidative deamination of monoamine neurotransmitters and dietary amines. Two pharmacological types with different substrate and inhibitor specificities were reported. Molecular cloning revealed that the two types of MAO were different genes expressed as different proteins with different functions. MAO A and B have identical intron–exon organization derived by duplication of a common ancestral gene thus they are termed isoenzymes. MAO A knockout mice exhibited aggression, the first clear evidence linking genes to behavior. MAO A KO mice exhibited autistic-like behaviors which could be prevented by reducing serotonin levels at an early developmental age (P1–P7) providing potential therapy. MAO B KO mice were non-aggressive and resistant to Parkinsongenic neurotoxin. More recently it was found that MAO A is overexpressed in prostate cancer and correlates with degree of malignancy. The oncogenic mechanism involves a ROS-activated AKT/FOXO1/TWIST1 signaling pathway. Deletion of MAO A reduced prostate cancer stem cells and suppressed invasive adenocarcinoma. MAO A was also overexpressed in classical Hodgkin lymphoma and glioma brain tumors. MAO B was overexpressed in glioma and non-small cell lung cancer. MAO A inhibitors reduce the growth of prostate cancer, drug sensitive and resistant gliomas and classical Hodgkin lymphoma, and enhance standard chemotherapy. Currently, we are developing NIR dye-conjugated clorgyline (MAO A inhibitor) as a novel dual therapeutic/diagnostic agent for cancer. A phase II clinical trial of MAO inhibitor for biochemical recurrent prostate cancer is ongoing. The role of MAO A and B in several cancer types opens new avenues for cancer therapies.
Similar content being viewed by others
Abbreviations
- AKT:
-
Protein kinase B
- cHL:
-
Classical Hodgkin lymphoma
- EBV:
-
Epstein–Barr virus
- FFPE:
-
Formalin-fixed paraffin-embedded
- FOXO1:
-
Forkhead box protein O1
- GLUT1:
-
Glucose transporter 1
- H2O2 :
-
Hydrogen peroxide
- HIF-1α:
-
Hypoxia-inducible factor 1-alpha
- HRPC:
-
Hormone refractory prostate cancer
- HRS:
-
Hodgkin Reed–Sternberg
- 5-HT:
-
5-Hydroxytryptamine, serotonin
- 5-HTT:
-
Serotonin transporter
- IAP:
-
Inhibitor of apoptosis protein
- MAO A:
-
Monoamine oxidase A
- MAO B:
-
Monoamine oxidase B
- NED:
-
Neuroendocrine differentiation
- NIR:
-
Near-infrared
- NMI:
-
NIR dye–MAO A inhibitor conjugate
- NRP-1:
-
Neuropilin-1
- OATPs:
-
Organic anion-transporting polypeptides
- pCPA:
-
p-Chloro-phenylalanine
- PHD3:
-
Prolyl hydroxylase 3
- PI3K:
-
Phosphoinositide 3-kinase
- PTSD:
-
Posttraumatic stress disorder
- PSA:
-
Prostate specific antigen
- ROS:
-
Reactive oxygen species
- TMZ:
-
Temozolomide
- TWIST1:
-
Twist family BHLH transcription factor 1
- VEGFA:
-
Vascular endothelial growth factor A
References
Bach AW, Lan NC, Johnson DL, Abell CW, BEmbenek ME, Kwan SW, Seeburg PH, Shih JC (1988) cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85:4934–4938
Bortolato M, Shih JC (2011) Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence. Int Rev Neurobiol 100:13–42
Bortolato M, Godar SC, Davarian S, Chen K, Shih JC (2009) Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice. Neuropsychopharmacology 34:2746–2757
Bortolato M, Godar SC, Alzghoul L, Zhang J, Darling RD, Simpson KL, Bini V, Chen K, Wellman CL, Lin RC, Shih JC (2013a) Monoamine oxidase A and A/B knockout mice display autistic-like features. Int J Neuropsychopharmacol 16:869–888
Bortolato M, Godar SC, Tambaro S, Devoto P, Chen K, Shih JC (2013b) Early postnatal inhibition of serotonin synthesis results in long-term reductions of perseverative and anxiety-like behaviors, but not aggression, in MAO A-deficient mice. Neuropharmacology 75:223–232
Bortolato M, Floris G, Shih JC (2018) From aggression to autism: new perspectives on the behavioral sequela of monoamine oxidase deficiency. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-018-1888-y
Brunner HG, Nelen M, Breakenfield XO, Ropers HH, van Oost BA (1993) Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 262:578–580
Camell CD, Sander J, Spadaro O, Lee A, Nguyen KY, Wing A, Goldberg EL, Youm YH, Brown CW, Elsworth J, Rodeheffer MS, Schultze JL, Dixit VD (2017) Inflammasome-driven catecholamine catabolism in macrophages blunts lipolysis during ageing. Nature 550:119–123
Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Poumin S, Muller U, Aquet M, Babinet C, Shih JC (1995) Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAO A. Science 268:1763–1766
Chen K, Holschneider DP, Wu W, Rebrin I, Shih JC (2004) A spontaneous point mutation produces monoamine oxidase A/B knock-out mice with greatly elevated monoamines and anxiety-like behavior. J Biol Chem 279:39645–39652
Chen K, Ou XM, Wu W, Chen G, Shih JC (2005) R1, a novel repressor of the human monoamine oxidase A. J Biol Chem 25:11552–11559
Chen K, Rebrin I, Cases O, Seif I, Shih JC (2007) Forebrain specific expression of monoamine oxidase A reduces neurotransmitter levels, restores the brain structure and rescues aggressive behavior in monoamine oxidase A deficient mice. J Biol Chem 282:115–123
Deshwal S, Di Sante M, Di Lisa F, Kaludercic N (2017) Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease. Curr Opin Pharmacol 33:64–69
Godar SC, Bortolato M, Castelli MP, Casti A, Casu A, Chen K, Ennas MG, Tambaro S, Shih JC (2014) The aggression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake. J Psychaitr Res 56:1–9
Gordon RR, Wu M, Huang CY, Harris WP, Sim HG, Lucas JM, Coleman I, Higano CS, Gulati R, True LD, Vessella R, Lange PH, Garzotto M, Beer TM, Nelson PS (2014) Chemotherapy induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. PLoS One 9:e104271
Grimsby J, Chen K, Wang LJ, lan NC, Shih JC (1991) Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci USA 88:3637–3641
Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD, Karoum F, Gal J, Shih JC (1997) Increased stress response and β B-deficient mice. Nat Genet 17:206–210
Gross M, Agus D, Dorff T, Pinski J, Quinn D, Shih JC (2016) Invited submission, a late breaking abstract “Interim analysis of phenelzine (a monoamine oxidase inhibitor) for non-metastatic recurrent prostate cancer”, October 30. Presented at Prostate Cancer Foundation Meeting, San Diego
Hare ML (1928) Tyramine oxidase: a new enzyme system in liver. Biochem J 22:968–979
Hintiryan H, Foster NN, Bowman I, Bay M, Song MY, Gou L, Yamashita S, Bienkowski MS, Zingg B, Zhu M, Yang XW, Shih JC, Toga AW, Dong HW (2016) The mouse cortico-striatal projectome. Nat Neurosci 19:1100–1114
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, Di Lisa F (2014) Monoamine oxidases as sources of oxidants in the heart. J Mol Cell Cardiol 73:34–42
Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408
Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, Jhaveri N, Groshen SL, Olenyuk BZ, Chen TC, Hofman FM, Shih JC (2016) Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget 7:13842–13853
Lan NC, Chen CH, Shih JC (1989a) Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 52:1652–1654
Lan NC, Heinzmann C, Gal A, Klisak I, Orth U, Grimsby J, Sparkes RS, Mohandas T, Shih JC (1989b) Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. Genomics 4:552–559
Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, Steidl C, Shih JC (2017) Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma. J Pathol 243:220–229
Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross ME, Shih JC (2018) Loss of MAO A in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene 37:5175–5190
Lin YC, Chang YT, Campbell M, Lin TP, Pan CC, Lee HC, Shih JC, Chang PC (2017) MAO A-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep 7:46338
Ou XM, Chen K, Shih JC (2004) Dual functions of transcription factors, transforming growth factor-beta-inducible early gene (TIEG)2 and Sp3, are mediated by CACCC element and Sp1 sites of human monoamine (MAO) B gene. J Biol Chem 279:21021–21028
Ou XM, Chen K, Shih JC (2006a) Glucocorticoid and androgen activation of monoamine oxidase A are regulated by R1 and SP1. J Biol Chem 281:21512–21525
Ou XM, Chen K, Shih J (2006b) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923–10928
Peehl DM, Coram M, Khine H, Reese S, Nolley R, Zhao H (2008) The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol 180:2206–2211
Scott AL, Bortolato M, Chen K, Shih JC (2008) Novel monoamine oxidase A knockout mice with human-like spontaneous mutation. Neuroreport 19:739–743
Sharpe MA, Baskin DS (2016) Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF-1α and with transcription factors Sp1 and Sp3. Oncotarget 7:3379–3393
Sharpe MA, Livingston AD, Gist TL, Ghosh P, Han J, Baskin DS (2015) Successful treatment of intracranial glioblastoma xenografts with a monoamine oxidase B-activated pro-drug. EBioMedicine 2:1122–1132
Sharpe MA, Raghavan S, Baskin DS (2018) PAM-OBG: a monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. Oncotarget 9:23923–23943
Shih JC (2004) Cloning, after cloning, knock-out mice, and physiological function of MAO A and B. Shih JC NeuroToxicology 25:21–30
Shih JC, Eiduson S (1969) Multiple forms of monoamine oxidase in developing brain. Nature 224:1309–1311
Shih JC, Thompson RF (1999c) Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 65:593–598
Shih JC, Chen K, Ridd MJ (1999a) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197–217
Shih JC, Ridd MJ, Chen K, Meehan WP, Kung M-P, Seif I, De Mayer E (1999b) Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A. Brain Res 835:104–112
Shih JC, Wu JB, Chen K (2011) Transcriptional regulation and multiple functions of MAO genes. J Neural Transm 118:979–986
Singh C, Bortolato M, Balic N, Godard SC, Scott AL, Chen K, Thompson RF, Shih JC (2013) Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proc Natl Acad Sci 110:12816–12821
Son B, Jun SY, Seo H, Youn H, Yang HJ, Kim W, Kim HK, Kang C, Youn B (2016) Inhibitory effect of traditional oriental medicine-derived monoamine oxidase B inhibitor on radioresistance of non-small cell lung cancer. Sci Rep 6:21986
Song MS, Matveychuk D, MacKenzie EM, Duchcherer M, Mousseau DD, Baker GB (2013) An update on amine oxidase inhibitors: multifaceted drugs. Prog Neuropsychopharmacol Biol Psychiatry 44:118–124
True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103:10991–10996
White TA, Kwon EM, Fu R, Lucas JM, Ostrander EA, Stanford JL, Nelson PS (2012) The monoamine oxidase A gene promoter repeat and prostate cancer risk. Prostate 72:1622–7162
Wong WK, Chen K, Shih JC (2001) Regulation of human monoamine oxidase B gene by Sp1 and Sp3. Mol Pharmacol 59:852–859
Wong WK, Ou X-M, Chen K, Shih JC (2002) Activation of human monoamine oxidase B gene expression by a protein kinase C, MAPK signal transduction pathway involves c-Jun and Egr-1. J Biol Chem 277:22222–22230
Wong WK, Chen K, Shih JC (2003) Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation. J Biol Chem 278:36227–36235
Wu JB, Chen K, Li Y, Lau YF, Shih JC (2009a) Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J 23:4029–4038
Wu JB, Chen K, Ou XM, Shih JC (2009b) Retinoic acid activates monoamine oxidase B promoter in human neuronal cells. J Biol Chem 284:16723–16735
Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, Stiles BL, Zhau HE, Shih JC, Chung LW (2014) Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest 124:2891–2908
Wu JB, Lin TP, Gallagher JD, Kushal S, Chung LW, Zhau HE, Olenyuk BZ, Shih JC (2015) Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth. J Am Chem Soc 137:2366–2374
Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati N (2015) Dual inhibition of survivin and MAO A synergistically impairs growth of PTEN-negative prostate cancer. Br J Cancer 113:242–251
Youdim MB, Collins GG, Sandler M (1969) Multiple forms of rat brain monoamine oxidase. Nature 223:626–628
Zhang Z, Chen K, Shih JC, Teng CT (2006) Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors. Mol Endocr 20:1547–1561
Zhu QS, Shih JC (1997) An extensive repeat structure down-regulates human monoamine oxidase A promoter activity independent of an initiator-like sequence. J Neurochem 69:1368–1373
Zhu QS, Grimsby J, Chen K, Shih JC (1992) Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci 12:4437–4446
Zhu QS, Chen K, Shih JC (1994) Bidirectional promoter of human monoamine oxidase A (MAO A) controlled by transcription factor Sp1. J Neurosci 14:7393–7403
Ziegler C, Richter J, Mahr M, Gajewska A, Schiele MA, Gehrmann A, Schmidt B, Lesch KP, Lang T, Helbig-Lang S, Pauli P, Kircher T, Reif A, Rief W, Vossbeck-Elsebusch AN, Arolt V, Wittchen HU, Hamm AO, Deckert J, Domschke K (2016) MAO A gene hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy. Transl Psychiatry 5(6):e773. https://doi.org/10.1038/tp.2016.41
Ziegler C, Wolf C, Schiele MA, Feric Bojic E, Kucukalic S, Sabic Dzananovic E et al (2018) Monoamine oxidase A gene methylation and its role in posttraumatic stress disorder: first evidence from the South Eastern Europe (SEE)-PTSD Study. Int J Neuropsychopharmacol 21:423–432
Acknowledgements
The work presented here was supported by NIH grants including two MERIT awards, grants from USC Trustee Tsai Family Fund, and the Boyd and Elsie Welin Professorship. The invaluable contributions of my long-time collaborator Dr. Kevin Chen are gratefully acknowledged. The contributions of international collaborators, graduate students, postdoctoral fellows, and research associates are deeply appreciated. The editing assistance of Frank Hong and Ronald Irwin is also gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
JCS is an inventor on issued US patents 9,771,625 and 9,675,620 related to MAO inhibitor-based compounds that target prostate and brain cancers.
Rights and permissions
About this article
Cite this article
Shih, J.C. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy. J Neural Transm 125, 1553–1566 (2018). https://doi.org/10.1007/s00702-018-1927-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-018-1927-8